Fibrinogen/Albumin Ratio (FAR) in Patients with Triple Negative Breast Cancer and Its Relationship with Epidermal Growth Factor Receptor Expression

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Rongshou Z, Kexin S, Siwei Z, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol. 2019;41(1):19–28. doi:10.3760/cma.j.issn.0253-3766.2019.01.005
   Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–2442. doi:10.1016/S0140-6736(16)32454-0
   PubMed Web of Science ®Google Scholar
• Lyons TG, Traina TA. Emerging novel therapeutics in triple-negative breast cancer. Adv Exp Med Biol. 2019;1152:377–399. doi:10.1007/978-3-030-20301-6_20
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Del Prete A, Allavena P, Santoro G, et al. Molecular pathways in cancer-related inflammation. Biochem Med. 2011;21(3):264–275. doi:10.11613/bm.2011.036
   Web of Science ®Google Scholar
• Zacharski LR, Meehan KR, Algarra SM, et al. Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metastasis Rev. 1992;11(3–4):421–431. doi:10.1007/BF01307191
   PubMed Web of Science ®Google Scholar
• Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin. 2016;74(4):405–412. doi:10.1684/abc.2016.1167
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost. 2019;45(4):413–422. doi:10.1055/s-0039-1688495
   PubMed Web of Science ®Google Scholar
• Usama SM, Park GK, Nomura S, et al. Role of albumin in accumulation and persistence of tumor-seeking cyanine dyes. Bioconjug Chem. 2020;31(2):248–259. doi:10.1021/acs.bioconjchem.9b00771
   PubMed Web of Science ®Google Scholar
• Xu WY, Zhang HH, Xiong JP, et al. Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. World J Gastroenterol. 2018;24(29):3281–3292. doi:10.3748/wjg.v24.i29.3281
   PubMed Web of Science ®Google Scholar
• Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts Prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:4925498. doi:10.1155/2018/4925498
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao G. Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis. Cancer Manag Res. 2019;11:3381–3393. doi:10.2147/CMAR.S198419
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wu C, Yan H, et al. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: a prognostic nomogram study. Clin Chim Acta. 2020;506:110–121. doi:10.1016/j.cca.2020.03.011
   PubMed Web of Science ®Google Scholar
• Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019;8:F1000. doi:10.12688/f1000research.18888.1
   PubMedGoogle Scholar
• Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi:10.4103/aam.aam_56_18
   PubMed Web of Science ®Google Scholar
• Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1
   PubMed Web of Science ®Google Scholar
• Wang H, Gao J, Bai M, et al. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2014;25(5):382–387. doi:10.3109/09537104.2013.827782
   PubMed Web of Science ®Google Scholar
• Suzuki T, Shimada H, Nanami T, et al. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer. Surg Today. 2016;46(12):1394–1401. doi:10.1007/s00595-016-1339-z
   PubMed Web of Science ®Google Scholar
• Zhou L, Ma S, Balde AI, et al. A retrospective propensity score matched study of the preoperative C-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer. Med Sci Monit. 2019;25:4342–4352. doi:10.12659/MSM.913684
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou Y, Xia S, et al. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. Cancer Biomark. 2020;28(4):537–547. doi:10.3233/CBM-201682
   PubMed Web of Science ®Google Scholar
• Jomrich G, Gruber ES, Winkler D, et al. Systemic Immune-Inflammation Index (SII) predicts poor survival in pancreatic cancer Patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–618. doi:10.1007/s11605-019-04187-z
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155–170. doi:10.3109/10408363.2011.599831
   PubMed Web of Science ®Google Scholar
• Sun F, Tan YA, Gao QF, et al. Circulating fibrinogen to pre-albumin ratio is a promising biomarker for diagnosis of colorectal cancer. J Clin Lab Anal. 2019;33(1):e22635. doi:10.1002/jcla.22635
   PubMed Web of Science ®Google Scholar
• Zhang J, Ruan J, Wang W, et al. Prognostic value of the combination of CEA and fibrinogen/albumin ratio in resectable Gastric cancer. Cancer Manag Res. 2020;12:2767–2775. doi:10.2147/CMAR.S246566
   PubMed Web of Science ®Google Scholar
• Cao X, Yidong Z, Feng M, et al. Effect of fibrinogen to albumin ratio on prognosis of operable breast cancer patients. Chin J Breast Dis. 2020;14(4):213–220.
   Google Scholar
• Lihua ZHENG, Feng LIU, Wei LI, et al. Relation between albumin to fibrinogen ratio and overall survival of breast cancer. Zhong Liu Fang Zhi Yan Jiu. 2020;47(2):102–107.
   Google Scholar
• Martino MM, Briquez PS, Ranga A, et al. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A. 2013;110(12):4563–4568. doi:10.1073/pnas.1221602110
   PubMed Web of Science ®Google Scholar
• Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology. 2010;25(2):85–101. doi:10.1152/physiol.00045.2009
   PubMed Web of Science ®Google Scholar
• Virizuela JA, Camblor-álvarez M, Luengo-Pérez LM, et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report. Clin Transl Oncol. 2018;20(5):619–629. doi:10.1007/s12094-017-1757-4
   PubMed Web of Science ®Google Scholar
• Talukdar S, Emdad L, Das SK, et al. EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res. 2020;147:161–188. doi:10.1016/bs.acr.2020.04.003
   PubMed Web of Science ®Google Scholar
• Jr RR. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395–411. doi:10.1016/j.phrs.2018.11.014
   PubMed Web of Science ®Google Scholar
• Xiaoli W, Deying X, Zhenzhen S, et al. Expression and prognostic significance of EGFR, p53, Ki-67 and AR in breast cancer. J Henan Univ Sci Tech. 2019;37(2):86–90.
   Google Scholar